Search
Advertisement
neetu chandra sharma
Neetu Chandra Sharma

Neetu Chandra Sharma

tvtn

neetu.chandra@aajtak.com

Neetu Chandra Sharma is a Senior Editor at Business Today, where she leads the magazine’s coverage of healthcare and pharmaceuticals. With over two decades of experience in top Indian newsrooms—including Mint, Hindustan Times, the India Today Group, ...

SHOW MORE...

Follow Neetu Chandra Sharma on:

He further said India must also accelerate electrification across transportation and industry.

BT Infra Summit 2026: Storage, green hydrogen key to India’s next renewable leap, says ReNew’s chief

by Neetu Chandra Sharma |Jul 31, 2026

Storage, green fuels and domestic manufacturing will drive the next phase of India’s clean energy transition, says Sumant Sinha, Founder, Chairman and CEO of ReNew.

The author also draws attention to the link between skin and conditions affecting the liver, thyroid, kidneys, gut and metabolism.

Book Review: The science of healthy skin

by Neetu Chandra Sharma |Jul 25, 2026

Delhi-based dermatologist Dr Deepali Bhardwaj explains the science behind healthy skin, separating medical evidence from popular skincare trends. 

The proposal has also turned industry attention to which companies are better placed to absorb higher costs if the duties are eventually implemented.

Trump's generic drug tariff plan: Who gains, who faces pressure and what's next?

by Neetu Chandra Sharma |Jul 25, 2026

Companies are unlikely to move manufacturing to the US overnight. Instead, they are expected to focus on product portfolios, export diversification and selective capacity expansion while awaiting clar...

Manipal already has around 2,400-2,500 beds under development, including projects in Mumbai and Raipur, and expects these additions to support its next leg of growth.

Ahead of mega ₹9,275-crore IPO, Manipal plans 3,000 new beds, eyes expansion

by Neetu Chandra Sharma |Jul 24, 2026

Hospital chain says higher occupancy, acquisitions and expansion into new markets will drive growth; July 29 IPO to leave it virtually debt-free.

Dr Reddy's Q1 Profit Hit By Semaglutide Issue, Weaker U.S. Sales

Dr Reddy's Q1 Profit Hit By Semaglutide Issue, Weaker U.S. Sales

by Neetu Chandra Sharma |Jul 24, 2026

Dr. Reddy's Laboratories reported a weak first quarter as net profit fell 69% year-on-year, hit by lower sales of its blockbuster cancer drug lenalidomide and a one-time provision related to a semaglu...

Doctors say COVID-19 and influenza now share many common symptoms, including fever, cough, sore throat, fatigue and body ache.

Is COVID-19 just another seasonal flu now? Experts say no

by Neetu Chandra Sharma |Jul 23, 2026

Experts say COVID-19 should not be dismissed as just another seasonal flu. While widespread immunity has reduced the severity of infection, the virus continues to hospitalise and kill vulnerable peopl...

AWS has incorporated that approach into Kiro, its agentic development environment.

AWS unveils new AI tools, expands Bedrock and Kiro capabilities

by Neetu Chandra Sharma |Jul 22, 2026

The cloud major has added new capabilities to Bedrock, Kiro and Strands Agents as it expands its AI software development portfolio.

Trump's 100% Pharma Tariff Plan: How Will Indian Drugmakers Respond To The U.S. Move?

Trump's 100% Pharma Tariff Plan: How Will Indian Drugmakers Respond To The U.S. Move?

by Sakshi Batra |Jul 22, 2026

India's pharmaceutical sector is back in focus after U.S. President Donald Trump proposed a 100% tariff on generic drug imports, while offering a two-year grace period before implementation. Business ...

The findings reflect the expansion underway across the hospital sector, with companies adding beds through greenfield and brownfield projects, partnerships and acquisitions.

Here’s what is fuelling India’s healthcare sector growth

by Neetu Chandra Sharma |Jul 22, 2026

Organised diagnostic companies also reported revenue growth of more than 15%, with average EBITDA margins above 25%.

The tariff announcement is significant for India, as the US is the country’s largest pharmaceutical export market, accounting for nearly a third of India’s drug exports by value.

Indian pharma seeks engagement with the US administration after Trump’s generic drug tariff plan

by Neetu Chandra Sharma |Jul 22, 2026

Industry says Indian companies have already invested in US manufacturing and remain critical to America’s generic drug supply, even as Trump pushes for greater domestic production.